ESMO: Padcev/Keytruda Combo Edges Closer To First-Line Bladder Cancer Filing

Big Boost For Seagen

 
• By Kevin Grogan
  
First-line approval is the target for Padcev/Keytruda combo • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D